Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pier Giovanni Baraldi

Showing results (71-80 of 159) with videos related to

Pageof 16
Sort By:
Arzneimittel-Forschung|March 20, 2003
Design, synthesis and in vitro cytotoxicity of a cis-dichloroplatinum (II) complex linked to the minor groove binder stallimycinPier Giovanni Baraldi, Mojgan Aghazadeh Tabrizi, Maria Giovanna Pavani, et al.
Journal of Medicinal Chemistry|January 23, 2004
Synthesis of nitro esters of prednisolone, new compounds combining pharmacological properties of both glucocorticoids and nitric oxidePier Giovanni Baraldi, Romeo Romagnoli, Maria Del Carmen Nuñez, et al.
Journal of Medicinal Chemistry|March 3, 2006
Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigationsGiorgia Pastorin, Tatiana Da Ros, Chiara Bolcato, et al.
Arzneimittel-Forschung|June 4, 2002
Synthesis, biological activity and molecular modeling studies of 1,2,3,4-tetrahydroisoquinoline derivatives as conformationally constrained analogues of KN62, a potent antagonist of the P2X7-receptor containing a tyrosine moietyPier Giovanni Baraldi, Rimma Makaeva, Maria Giovanna Pavani, et al.
Biochemical Pharmacology|January 26, 2010
Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptorsStefania Gessi, Valeria Sacchetto, Eleonora Fogli, et al.
Pain|March 23, 2013
Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain modelsFabrizio Vincenzi, Martina Targa, Carmen Corciulo, et al.
Journal of Medicinal Chemistry|September 19, 2003
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigationGiorgia Pastorin, Tatiana Da Ros, Giampiero Spalluto, et al.
European Journal of Medicinal Chemistry|May 27, 2014
Design, synthesis and biological evaluation of arylcinnamide hybrid derivatives as novel anticancer agentsRomeo Romagnoli, Pier Giovanni Baraldi, Maria Kimatrai Salvador, et al.
Journal of Medicinal Chemistry|July 11, 2006
Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein modelsAndrea Tafi, Cesare Bernardini, Maurizio Botta, et al.
Journal of Medicinal Chemistry|February 8, 2002
Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonistsPier Giovanni Baraldi, Barbara Cacciari, Stefano Moro, et al.
Pageof 16

Showing results (71-80 of 159) with videos related to

Sort By:
Pageof 16
Arzneimittel-Forschung|March 20, 2003
Design, synthesis and in vitro cytotoxicity of a cis-dichloroplatinum (II) complex linked to the minor groove binder stallimycinPier Giovanni Baraldi, Mojgan Aghazadeh Tabrizi, Maria Giovanna Pavani, et al.
Journal of Medicinal Chemistry|January 23, 2004
Synthesis of nitro esters of prednisolone, new compounds combining pharmacological properties of both glucocorticoids and nitric oxidePier Giovanni Baraldi, Romeo Romagnoli, Maria Del Carmen Nuñez, et al.
Journal of Medicinal Chemistry|March 3, 2006
Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigationsGiorgia Pastorin, Tatiana Da Ros, Chiara Bolcato, et al.
Arzneimittel-Forschung|June 4, 2002
Synthesis, biological activity and molecular modeling studies of 1,2,3,4-tetrahydroisoquinoline derivatives as conformationally constrained analogues of KN62, a potent antagonist of the P2X7-receptor containing a tyrosine moietyPier Giovanni Baraldi, Rimma Makaeva, Maria Giovanna Pavani, et al.
Biochemical Pharmacology|January 26, 2010
Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptorsStefania Gessi, Valeria Sacchetto, Eleonora Fogli, et al.
Pain|March 23, 2013
Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain modelsFabrizio Vincenzi, Martina Targa, Carmen Corciulo, et al.
Journal of Medicinal Chemistry|September 19, 2003
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigationGiorgia Pastorin, Tatiana Da Ros, Giampiero Spalluto, et al.
European Journal of Medicinal Chemistry|May 27, 2014
Design, synthesis and biological evaluation of arylcinnamide hybrid derivatives as novel anticancer agentsRomeo Romagnoli, Pier Giovanni Baraldi, Maria Kimatrai Salvador, et al.
Journal of Medicinal Chemistry|July 11, 2006
Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein modelsAndrea Tafi, Cesare Bernardini, Maurizio Botta, et al.
Journal of Medicinal Chemistry|February 8, 2002
Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonistsPier Giovanni Baraldi, Barbara Cacciari, Stefano Moro, et al.
Pageof 16